Overview
Pharmaceutical

Cyfuse Biomedical K.K.

Cyfuse Biomedical is a regenerative medicine venture that develops and commercializes three-dimensional cell-only tissue and organ products ('3D cell products') using its proprietary platform technology combining spheroids and bio-3D printers. The company operates across three segments: (1) regenerative medicine, developing pipeline products such as cell-based nerve conduits, osteochondral grafts, and vascular grafts; (2) drug discovery support, providing 3D cell-based in vitro evaluation tools (including human liver function models) to pharmaceutical and CRO clients; and (3) device, developing and selling bio-3D printer systems. Its key competitive strength lies in fabricating transplantable tissues without artificial scaffolding materials, enabling high biocompatibility and reduced rejection risk.

Market Cap
¥5.74B
US$36.6M
EV
¥3.58B
US$22.9M
Stock¥569▼-2.07%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
2.3
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-27.6%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
5.74BUS$36.6MMarket Cap1.23BUS$7.86M+ Debt3.39BUS$21.6M− Cash0.00BUS$0.00M− Inv. Sec.3.58BUS$22.9MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.71US$4.52M'21/120.37US$2.39M'22/120.06US$0.39M'23/120.05US$0.34M'24/120.23US$1.47M'25/12
EBITDA 5Y (¥B)
0.09US$0.57M'21/12-0.37-US$2.36M'22/12-0.66-US$4.20M'23/12-0.86-US$5.48M'24/12-0.79-US$5.05M'25/12
Net Income 5Y (¥B)
-0.47-US$3.02M'22/12-0.59-US$3.76M'23/12-0.87-US$5.56M'24/12-0.76-US$4.87M'25/12
Capital Structure
67%
33%
EquityD/E 0.49xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
2.41US$15.4M0.57US$3.63M'21/124.44US$28.3M0.91US$5.79M'22/123.87US$24.7M0.91US$5.82M'23/123.05US$19.5M0.85US$5.44M'24/123.73US$23.8M1.31US$8.37M'25/12
Shareholders
Top 10 hold 34.7%
1
SBI SECURITIES Co., Ltd.
5.72%
2
Shizuka AKIEDA
5.51%
3
SBI Ventures Two Co., Ltd.
4.58%
4
Masahiro SANJO
4.15%
5
KURARAY CO.,LTD.
3.48%
6
Masao KONISHI
3.10%
7
Koichi NAKAYAMA
2.41%
8
SBI Shinsei Bank,Limited
2.20%
9
PHC Holdings Corporation
1.83%
10
Rakuten Securities, Inc. (Joint Account)
1.76%
Management
8 officers
Shizuka AKIEDA
Representative Director
Apr 2004 Researcher, Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University Apr 2007 Academic Researcher, Department of Pathology and Pathophysiology, Graduate School of Medical Sciences, Kyushu University Apr 2010 Academic Researcher, Department of Orthopaedic Surgery, Kyushu University Hospital Oct 2010 Joined the Company Oct 2013 Member of Working Group and Task Force, Human Cell Manufacturing System Development, Regenerative Medicine Field, Ministry of Economy, Trade and Industry / Japan Agency for Medical Research and Development (AMED) Sep 2016 Director, General Manager of Cell Product Development Division, the Company Oct 2016 Director and Executive Officer, General Manager of Cell Product Development Division, the Company Mar 2018 Representative Director, President and Executive Officer, the Company (current)
1976-12-02
Masahiro SANJO
Director, CFO, General Manager of Corporate Management Division
Aug 2000 Joined Riso Kyoiku Co., Ltd. (now Riso Kyoiku Group Co., Ltd.) Mar 2008 Graduated from Chuo University Graduate School of Law Nov 2008 Joined Symbio Pharmaceuticals Co., Ltd. Dec 2015 General Manager, Corporate Management Division, the Company Oct 2017 Executive Officer, General Manager of Corporate Management Division, the Company Mar 2018 Director, Executive Officer, CFO and General Manager of Corporate Management Division, the Company (current)
1976-11-20
Yasuto KISHII
Director, General Manager of Business Promotion Division
Apr 2003 Joined Micron Japan, Ltd. Oct 2008 Joined Mitsubishi Electric Corporation Apr 2015 Manager, System Development Division, the Company Apr 2022 General Manager, Business Promotion Division, the Company Jan 2024 Executive Officer, General Manager of Business Promotion Division, the Company Mar 2026 Director, Executive Officer, General Manager of Business Promotion Division, the Company (current)
1980-02-16
Yasuhiro YOSHIOKA
Outside Director
Apr 1980 Joined Fuji Photo Film Co., Ltd. (now FUJIFILM Corporation) Nov 2008 General Manager, Life Science Research Laboratories, FUJIFILM Corporation Jul 2011 Fellow, R&D Headquarters, FUJIFILM Corporation Apr 2012 Member, Life Innovation Strategy Council, Cabinet Office Sep 2013 Executive Officer, General Manager of Regenerative Medicine Research Institute, FUJIFILM Corporation Apr 2014 Chairman, Stem Cell Evaluation Technology Research Association Jul 2015 Fellow, R&D Headquarters, FUJIFILM Corporation Aug 2015 Advisor for Lipid Field, Japan Agency for Medical Research and Development (AMED) Jun 2016 Specially Appointed Professor, Kyoto Prefectural University of Medicine Jul 2016 Senior Advisor, FUJIFILM Corporation Jul 2017 Director, Stem Cell Evaluation Technology Research Association Apr 2018 Technical Advisor, the Company Mar 2019 Outside Director, the Company (current)
1955-09-27
Kunihiko SUZUKI
Outside Director
Apr 1982 Joined Esso Sekiyu K.K. (now ENEOS Corporation) Mar 1988 Master of Business Administration (MBA), Graduate School of Business and Project Management, Keio University Aug 1988 Joined Nikko Securities Co., Ltd. (now SMBC Nikko Securities Inc.) Jul 2001 President, Nikko Bank (Luxembourg) S.A. (now SMBC Nikko Bank (Luxembourg) S.A.) Mar 2006 Joined MEDINET Co., Ltd. Oct 2013 Representative Director, President, MEDINET Co., Ltd. Dec 2018 Director, Vice President, MEDINET Co., Ltd. Dec 2020 Director, MEDINET Co., Ltd. Dec 2020 Management Advisor, the Company Mar 2021 Outside Director, the Company (current) Jun 2022 Outside Audit & Supervisory Board Member, Cellfiber Co., Ltd. (current) Oct 2022 Advisor, MEDINET Co., Ltd. (current)
1959-05-06
Yusuke MIZUGUCHI
Full-time Audit and Supervisory Board Member
Apr 2005 Joined NEC Systems Construction, Ltd. (now NEC Networks & System Integration Corporation) Aug 2007 Joined Triax Co., Ltd. (now Scala Communications, Inc.) Oct 2012 Joined Arata Audit Corporation (now PricewaterhouseCoopers Japan LLC) Jul 2016 Registered as Certified Public Accountant Sep 2023 Registered as Certified Tax Accountant Sep 2023 Representative, Mizuguchi Certified Public Accountant and Tax Accountant Office (current) May 2025 Provisional Outside Audit and Supervisory Board Member, the Company Aug 2025 Outside Audit and Supervisory Board Member, the Company (current)
1982-09-25
Takao HIROSE
Audit and Supervisory Board Member
Apr 1997 Registered as attorney-at-law, Tomotsune Kimura Tomi Law Office (now Anderson Mori & Tomotsune) May 2004 Registered as attorney in New York State Jan 2005 Partner Attorney, Anderson Mori & Tomotsune (current) Jun 2007 Outside Audit and Supervisory Board Member, Roland DG Corporation Jun 2010 Outside Director, Roland DG Corporation Apr 2018 Advisor, the Company Jun 2018 Outside Audit and Supervisory Board Member, the Company (current) Dec 2020 Outside Audit and Supervisory Board Member, CoreConcept Technologies Inc. Mar 2021 Outside Director (Audit and Supervisory Committee Member), CoreConcept Technologies Inc. (current) Dec 2021 Outside Director, Hamamatsu Photonics K.K. (current)
1971-06-28
Kazuya ODA
Audit and Supervisory Board Member
Apr 1986 Joined Kaneka Corporation Mar 1997 Completed Master's Program in Policy Science, Graduate School of Policy and Management, Doshisha University Nov 2012 Senior Manager, Foamed Resin Products Division, and Business Creation General Leader, Kaneka Corporation Apr 2016 President, Tamai Kasei Co., Ltd. (until Sep 2017) Apr 2019 General Manager, F&R.TSV Epelan Department, Kaneka Corporation Mar 2021 Outside Audit and Supervisory Board Member, the Company (current) Apr 2021 Director, Kaneka Corporation Apr 2022 Representative Director, Mirei-ka Co., Ltd. (current)
1961-07-19
Large Shareholding Reports
SBI Ventures Two Co., Ltd.
2026-05-12
4.64%→4.64%
Annual report (as of 2026-06-30): 4.58%
Shizuka AKIEDA
2026-04-28
8.33%→7.31%
Annual report (as of 2026-06-30): 5.51%
SBI Ventures Two Co., Ltd.
2026-04-27
4.64%→4.64%
Annual report (as of 2026-06-30): 4.58%
SBI Ventures Two Co., Ltd.
2026-01-23
4.85%→4.64%
Annual report (as of 2026-06-30): 4.58%
SBI Ventures Two Co., Ltd.
2025-10-01
4.88%→4.85%
Annual report (as of 2026-06-30): 4.58%
SBI Securities Co., Ltd.
2025-09-26
6.31%→5.33%
SBI Securities Co., Ltd.
2025-09-12
7.31%→6.31%
SBI Securities Co., Ltd.
2025-09-02
8.42%→7.31%
SBI Securities Co., Ltd.
2025-08-22
10.45%→8.42%
SBI Securities Co., Ltd.
2025-08-18
11.62%→10.45%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-14
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-14
Q2 Earnings Flash
FY ending Dec 2026
TDnet
2026-05-15
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-05-12
Large Shareholding Report
EDINET
2026-04-28
Large Shareholding Report
EDINET
2026-04-27
Large Shareholding Report
EDINET
2026-03-27
Annual Securities Report
Period: Jan 2025 – Dec 2025
EDINET
2026-01-23
Large Shareholding Report
EDINET
2025-12-24
Securities Registration Statement
TDnet
2025-11-14
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-10-01
Large Shareholding Report
EDINET
2025-09-26
Large Shareholding Report
EDINET
2025-09-12
Large Shareholding Report
EDINET
2025-09-02
Large Shareholding Report
EDINET
2025-08-22
Large Shareholding Report
EDINET
2025-08-18
Large Shareholding Report
EDINET
2025-08-14
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
EDINET
2025-05-30
Securities Registration Statement
TDnet
2025-05-15
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-26
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-14
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-15
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-27
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-14
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-14
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-05-15
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-28
Annual Securities Report
Period: Jan 2022 – Dec 2022
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →